Blog

Photo of Manni Mohyuddin from patientpower.info

Jun 7, 2024, 14:45

Manni Mohyuddin on DREAMM-7

Manni Mohyuddin shared on X/Twitter:

“In DREAMM-7 (bela/bort/dex vs dara/bort/dex).

Only 34% of pts len refractory.
POLLUX trial showed PFS of 45 months with dara/len/dex
Would bela/velcade/dex (PFS=37 mo) beat DRd for len sensitive patients?

Answer is clear:

If len/dara sensitive at relapse, use dara/len/dex!

I do not think we will get such results with Bela/bortezomib/dex in a US population that is increasing both Dara and Len refractory at first relapse.

PFS will likely be very modest.

Some food for a (controversial thought). How much PFS2 do we sacrifice with our current approach to treating myeloma?”

Manni Mohyuddin on DREAMM-7

Source: Manni Mohyuddin/X

Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.

bela/bort/dex vs dara/bort/dex cancer Dara refractory DREAMM-7 Len refractory len sensitive patients Manni Mohyuddin OncoDaily Oncology PFS POLLUX trial treating myeloma US population

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage